论文部分内容阅读
目的探讨行经尿道电切术的表浅性膀胱癌患者应用吡柔比星不同灌注时间治疗效果和安全性。方法行经尿道电切术表浅性膀胱癌患者112例,随机分为观察组和对照组各56例。2组均于术后14 d给予吡柔比星灌注治疗,观察组灌注治疗时间30 min/次,对照组15 min/次,2组灌注频率均为每周1次,每个疗程8次,连续治疗2个疗程。随访24个月,比较2组不良反应发生率、复发率和远期生存率。结果观察组治疗后8、12、24个月复发率(3.57%,5.36%,7.14%)低于对照组(8.93%,12.50%,19.64%)(P<0.05);观察组治疗后12,18,24个月生存率(100.00%,96.43%,92.86%)高于对照组(92.86%,87.50%,80.36%)(P<0.05);治疗期间观察组粒细胞减少、膀胱刺激征、血小板减少发生率(26.79%,21.43%,5.36%)高于对照组(7.14%,8.93%,0)(P<0.05)。结论行经尿道电切术的表浅性膀胱癌患者应用吡柔比星30 min/次灌注治疗可降低远期复发率,提高远期生存率,但不良反应发生率较高,临床需结合患者情况选择合适灌注治疗时间。
Objective To investigate the efficacy and safety of pirarubicin with different perfusion time in patients with superficial bladder cancer who underwent transurethral resection of the urethra. Methods One hundred and twelve patients with superficial bladder cancer who underwent transurethral resection of the bladder were randomly divided into observation group (56 cases) and control group (56 cases). Both groups were given pirarubicin 14 days after the operation, the observation group was given 30 minutes of treatment and 15 minutes of the control. The perfusion frequency of the two groups was once a week for 8 times, Continuous treatment of 2 courses. The patients were followed up for 24 months. The incidence of adverse reactions, relapse rate and long-term survival rate were compared between the two groups. Results The recurrence rates (3.57%, 5.36%, 7.14%) in observation group at 8, 12 and 24 months after treatment were lower than those in control group (8.93%, 12.50% and 19.64%, P < The survival rates of 18 and 24 months (100.00%, 96.43%, 92.86%) were higher than that of the control group (92.86%, 87.50% and 80.36% respectively) (P <0.05); The observation group had decreased neutropenia, irritation of the bladder, The incidence of reduction (26.79%, 21.43%, 5.36%) was higher than that of the control group (7.14%, 8.93%, 0) (P <0.05). Conclusion Transurethral resection of superficial bladder cancer patients with pirarubicin 30 min / perfusion therapy can reduce the long-term recurrence rate and improve long-term survival, but the incidence of adverse reactions higher, the clinical need to be combined with the patient’s condition Choose the appropriate perfusion treatment time.